중증 고중성지방혈증: FCS 이외의 중증 고중성지방혈증 환자군에서의 유효성은 실제 임상 사용 실적과 연구자 주도 임상시험을 통해 지속적으로 검증되고 있습니다.
현재 진행 중인 아포리포단백 C-III 억제에 대한 임상 연구는 이 치료 경로의 장기적인 유용성을 지원하고 있습니다.
3. 지역적 확장
WAYLIVRA는 유럽, 영국, 소비(Sobi)를 통해 선별된 국제 시장에서 승인 및 시판되고 있습니다.
희귀질환 시장으로의 확대는 희귀의약품 제도와 얼리 액세스 프로그램을 통해 지원되고 있습니다.
유럽에서 질병에 대한 인식이 높아지고 진단 프로그램이 확대됨에 따라 적격 환자 발굴이 가속화되고 있습니다.
4. 신규 적응증 승인
웨이리브라는 가족성 고콜레스테롤혈증(FCS)에 대한 유럽 규제 당국의 승인을 받아 이 환자군을 위한 최초의 질환 개량형 치료제 중 하나가 되었습니다.
승인 이후 진행된 연구와 실제 임상시험 프로그램은 향후 보다 광범위한 트리글리세리드 저하 적응증에 대한 논의를 지원하고 있습니다.
규제 당국의 승인을 통해 웨이리브라는 희귀 지질 이상증에 대한 표준 치료제로서의 지위를 확립했습니다.
5. 견고한 수량 모멘텀
환자 수는 적지만, 전문의의 채택과 좋은 임상결과에 힘입어 웨이리브라 처방은 꾸준히 증가하고 있습니다.
실제 데이터에서 유의미한 트리글리세리드 수치 감소와 췌장염으로 인한 입원 건수 감소가 확인되어 치료의 지속적인 채택을 지원하고 있습니다.
모니터링 프로토콜과 안전 관리 전략의 최적화에 따라 치료 지속율이 향상되고 있습니다.
6. 경쟁 차별화 및 시장 동향
WAYLIVRA는 유전자를 표적으로 하는 안티센스 치료제로 증상 관리뿐만 아니라 FCS의 근본 원인을 해결합니다.
피하주사를 통한 자가주사 프로파일로 외래 치료가 가능합니다.
RNA 기반 의약품과 희귀질환 치료의 혁신을 향한 광범위한 추세는 장기적인 시장 지위를 강력하게 지원하고 있습니다.
리얼월드에비던스(RWE)에 대한 의존도가 높아짐에 따라 초희귀질환 시장에서 보험사의 수용성이 향상되고 있습니다.
WAYLIVRA의 최근 발전
Sobi는 유럽 전역에 WAYLIVRA의 접근성을 확대하고 희귀질환 진단 네트워크를 강화하기 위해 지속적으로 투자하고 있습니다.
장기 연장 및 리얼월드 레지스트리 데이터는 이 약물이 중성지방 감소 효과를 지속시키고 췌장염 위험을 감소시키는 능력을 입증했습니다.
Ionis는 차세대 아포C-III 억제제(올레자르센 등)의 개발을 진행하고 있으며, WAYLIVRA가 확립한 작용기전을 입증하는 동시에 이 약제군에 대한 임상적 관심을 유지하고 있습니다.
WAYLIVRA의 주요 7개국(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)에 대해 조사 분석했으며, 각국 시장 규모와 예측, 연구개발(R&D) 활동, 경쟁 구도 등의 정보를 전해드립니다.
목차
제1장 리포트의 개요
제2장 가족성 부분 지방이영양증 및 제1형 고지단백혈증 등의 승인된 적응증, 고중성지방혈증 등의 잠재적 적응증에서 WAYLIVRA의 개요
제3장 WAYLIVRA의 경쟁 상황(출시 치료법)
제4장 경쟁 구도(후기 단계 신WAYLIVRA 요법)
제5장 WAYLIVRA 시장 평가
제6장 WAYLIVRA SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 소개
제12장 리포트 구입 옵션
KSA
영문 목차
영문목차
Key Factors Driving WAYLIVRA Growth
1. Market Share Gains and New Patient Starts
WAYLIVRA (volanesorsen), developed by Ionis Pharmaceuticals and commercialized by Akcea/Swedish Orphan Biovitrum (Sobi), is a first-in-class antisense oligonucleotide therapy for familial chylomicronemia syndrome (FCS).
The drug has captured a significant share of the ultra-rare FCS market, where treatment options are extremely limited.
New patient starts are being driven by improved genetic testing, better disease recognition, and referral to specialized lipid clinics.
2. Expansion Across Key Indications
Familial Chylomicronemia Syndrome (FCS): WAYLIVRA reduces apolipoprotein C-III, leading to substantial triglyceride reductions and fewer pancreatitis episodes.
Severe Hypertriglyceridemia: Real-world use and investigator-led studies continue to explore benefit in non-FCS severe hypertriglyceridemia populations.
Ongoing clinical research into apoC-III inhibition is reinforcing the long-term relevance of this therapeutic pathway.
3. Geographic Expansion
WAYLIVRA is approved and marketed in Europe, the UK, and select international markets through Sobi.
Expansion into additional rare-disease markets is supported by orphan drug frameworks and early access programs.
Increased disease awareness and diagnostic programs in Europe are accelerating identification of eligible patients.
4. New Indication Approvals
WAYLIVRA received European regulatory approval for FCS, marking one of the first disease-modifying treatments for this population.
Post-authorization studies and real-world evidence programs are supporting discussions around broader triglyceride-lowering indications in the future.
Regulatory success has positioned WAYLIVRA as a benchmark therapy in rare lipid disorders.
5. Strong Volume Momentum
Despite a small patient pool, WAYLIVRA demonstrates steady prescription growth driven by specialist uptake and positive clinical outcomes.
Real-world data show meaningful triglyceride reductions and fewer pancreatitis hospitalizations, supporting continued therapy adoption.
Treatment persistence is improving as monitoring protocols and safety management strategies are optimized.
6. Competitive Differentiation and Market Trends
WAYLIVRA is a genetically targeted antisense therapy, addressing the root cause of FCS rather than just symptom management.
Its subcutaneous, self-administered profile allows outpatient treatment.
The broader trend toward RNA-based medicines and rare disease innovation strongly supports long-term market positioning.
Growing reliance on real-world evidence (RWE) is improving payer acceptance in ultra-orphan markets.
WAYLIVRA Recent Developments
Sobi continues to invest in expanding access to WAYLIVRA across Europe and strengthening rare-disease diagnostic networks.
Long-term extension and real-world registry data have reinforced the drug's ability to sustain triglyceride reduction and reduce pancreatitis risk.
Ionis has advanced next-generation apoC-III inhibitors (e.g., olezarsen), validating the mechanism established by WAYLIVRA and sustaining clinical interest in the class.
"WAYLIVRA Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of WAYLIVRA for approved indications like Familial partial lipodystrophy and Hyperlipoproteinaemia type I; as well as potential indication like Hypertriglyceridaemia in the 7MM. A detailed picture of WAYLIVRA's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the WAYLIVRA for approved and potential indications. The WAYLIVRA market report provides insights about WAYLIVRA's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current WAYLIVRA performance, future market assessments inclusive of the WAYLIVRA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of WAYLIVRA sales forecasts, along with factors driving its market.
WAYLIVRA Drug Summary
WAYLIVRA (Volanesorsen) is an antisense oligonucleotide approved as an adjunct to diet for treating adult patients with genetically confirmed familial chylomicronemia syndrome (FCS), a rare autosomal recessive disorder caused by mutations in lipoprotein lipase (LPL) pathway genes (e.g., LPL, APOC2, GPIHBP1, LMF1) leading to impaired clearance of triglyceride-rich chylomicrons, resulting in severe fasting hypertriglyceridemia (>885 mg/dL or 10 mmol/L), recurrent pancreatitis, abdominal pain, hepatosplenomegaly, and eruptive xanthomas. Administered subcutaneously at 285 mg weekly for 3 months then every 2 weeks (adjusted based on platelet counts and triglyceride response), volanesorsen binds to apoC-III mRNA in hepatocytes via the 3' untranslated region, triggering RNase H-mediated degradation to reduce apoC-III protein synthesis by ~80-90%; since apoC-III inhibits LPL and promotes hepatic lipoprotein production, its suppression enhances remnant lipoprotein clearance through LPL-independent pathways, lowering fasting triglycerides by a mean 77% (vs. 18% placebo) at 3 months in the Phase III APPROACH trial, reducing pancreatitis incidence, and improving lipid parameters despite potential rises in LDL-C. The report provides WAYLIVRA's sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the WAYLIVRA Market Report
The report provides insights into:
A comprehensive product overview including the WAYLIVRA MoA, description, dosage and administration, research and development activities in approved indications like Familial partial lipodystrophy and Hyperlipoproteinaemia type I; as well as potential indication like Hypertriglyceridaemia.
Elaborated details on WAYLIVRA regulatory milestones and other development activities have been provided in WAYLIVRA market report.
The report also highlights WAYLIVRA's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
The WAYLIVRA market report also covers the patents information, generic entry and impact on cost cut.
The WAYLIVRA market report contains current and forecasted WAYLIVRA sales for approved and potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The WAYLIVRA market report also features the SWOT analysis with analyst views for WAYLIVRA in approved and potential indications.
Methodology:
The WAYLIVRA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
WAYLIVRA Analytical Perspective by DelveInsight
In-depth WAYLIVRA Market Assessment
This WAYLIVRA sales market forecast report provides a detailed market assessment of WAYLIVRA for approved indications like Familial partial lipodystrophy and Hyperlipoproteinaemia type I; as well as potential indication like Hypertriglyceridaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted WAYLIVRA sales data uptil 2034.
WAYLIVRA Clinical Assessment
The WAYLIVRA market report provides the clinical trials information of WAYLIVRA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
WAYLIVRA Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
WAYLIVRA Market Potential & Revenue Forecast
Projected market size for the WAYLIVRA and its key indications
Commercial partnerships, licensing deals, and M&A activity
WAYLIVRA Clinical Differentiation
WAYLIVRA Efficacy & safety advantages over existing drugs
WAYLIVRA Unique selling points
WAYLIVRA Market Report Highlights
In the coming years, the WAYLIVRA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The WAYLIVRA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence WAYLIVRA's dominance.
Other emerging products for Familial partial lipodystrophy and Hyperlipoproteinaemia type I; as well as potential indication like Hypertriglyceridaemia are expected to give tough market competition to WAYLIVRA and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of WAYLIVRA in approved and potential indications.
Analyse WAYLIVRA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted WAYLIVRA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of WAYLIVRA in approved and potential indications.
Key Questions:
What is the class of therapy, route of administration and mechanism of action of WAYLIVRA? How strong is WAYLIVRA's clinical and commercial performance?
What is WAYLIVRA's clinical trial status in each individual indications such as Familial partial lipodystrophy and Hyperlipoproteinaemia type I; as well as potential indication like Hypertriglyceridaemia and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the WAYLIVRA Manufacturers?
What are the key designations that have been granted to WAYLIVRA for approved and potential indications? How are they going to impact WAYLIVRA's penetration in various geographies?
What is the current and forecasted WAYLIVRA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of WAYLIVRA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to WAYLIVRA for approved and potential indications?
Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
How cost-effective is WAYLIVRA? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
1. Report Introduction
2. WAYLIVRA Overview in approved indications like Familial partial lipodystrophy and Hyperlipoproteinaemia type I; as well as potential indication like Hypertriglyceridaemia
